Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEZIN, Julien
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOORE, Nicholas
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMANSIAUX, Yohann
dc.contributor.authorSTEG, P. G.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
dc.date.accessioned2020-05-15T10:18:51Z
dc.date.available2020-05-15T10:18:51Z
dc.date.issued2019
dc.identifier.issn1555-7162 (Electronic) 0002-9343 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/7588
dc.description.abstractEnOBJECTIVES: The benefits of initiating statins in the elderly remains debated. We evaluated the effects of initiating statins in the elderly, according to cardiovascular risk. METHODS: This population-based cohort study used data of the representative sample of the French healthcare system database for the 2008-2015 period. New users of statins, aged 75 years and above were dynamically included in the cohort and matched 1:1 to statin non-users on age, gender, numbers of different drugs dispensed and medical consultations, and cardiovascular history. Patients were classified in three cardiovascular risk groups: secondary prevention (history of coronary heart disease), primary prevention with modifiable risk factors (diabetes or cardiovascular medications), and primary prevention without modifiable risk factor (none of the above). Effect of cumulative use of statins on occurrence of acute coronary syndrome or all-cause death was analyzed by using multivariable time-dependent Cox models stratified on cardiovascular risk at inclusion. RESULTS: Among the 7284 patients included, median follow-up was 4.7 years. Cumulative use of statins was associated with a lower risk of outcomes in the primary prevention with modifiable risk factors group (adjusted hazard ratio 0.93 per year of use; 95% confidence interval 0.89-0.96; p<0.01), and in the secondary prevention group (0.75; 0.63-0.90; p<0.01) but not in the primary prevention without modifiable risk factor group (1.01; 0.86-1.18; p=0.92). CONCLUSIONS: Statin treatment was not associated with a reduction in acute coronary syndrome or all-cause death in elderly without modifiable cardiovascular risk factor treated in primary prevention.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enReal-Life Benefits of Statins for Cardiovascular Prevention in Elderly Subjects: A Population-Based Cohort Study
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.amjmed.2018.12.032en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30660573en_US
bordeaux.journalThe American Journal of Medicineen_US
bordeaux.page740-748 e7en_US
bordeaux.volume132en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03211447
hal.version1
hal.date.transferred2021-04-28T15:03:12Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=The%20American%20Journal%20of%20Medicine&amp;rft.date=2019&amp;rft.volume=132&amp;rft.issue=6&amp;rft.spage=740-748%20e7&amp;rft.epage=740-748%20e7&amp;rft.eissn=1555-7162%20(Electronic)%200002-9343%20(Linking)&amp;rft.issn=1555-7162%20(Electronic)%200002-9343%20(Linking)&amp;rft.au=BEZIN,%20Julien&amp;MOORE,%20Nicholas&amp;MANSIAUX,%20Yohann&amp;STEG,%20P.%20G.&amp;PARIENTE,%20Antoine&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée